Iovance Biotherapeutics Stock Forecast, Price & News

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics or view top-rated stocks.

How has Iovance Biotherapeutics' stock price been impacted by Coronavirus?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have decreased by 37.0% and is now trading at $18.64.
View which stocks have been most impacted by COVID-19.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. During the same period in the prior year, the business earned ($0.40) earnings per share.
View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

12 analysts have issued 1 year target prices for Iovance Biotherapeutics' stock. Their forecasts range from $20.00 to $51.00. On average, they expect Iovance Biotherapeutics' share price to reach $38.20 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:

• Frederick G. Vogt, President, CEO, Secretary & General Counsel
• Igor P. Bilinsky, Chief Operating Officer
• Jean-Marc Bellemin, CFO & Principal Accounting Officer
• Friedrich Graf Finckenstein, Chief Medical Officer
• Sara Pellegrino, VP-Investor Relations & Public Relations

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Exelixis (EXEL), Abcam (ABCM), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), Twist Bioscience (TWST), Adagio Therapeutics (ADGI), Adaptive Biotechnologies (ADPT) and Ablynx (ABLYF).
View all of IOVA's competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.32%), Wellington Management Group LLP (5.67%), BlackRock Inc. (4.43%), Sumitomo Mitsui Trust Holdings Inc. (4.12%), Nikko Asset Management Americas Inc. (4.07%) and Franklin Resources Inc. (4.00%).
View institutional ownership trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Franklin Resources Inc., Goldman Sachs Group Inc., Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Jane Street Group LLC, and Artisan Partners Limited Partnership.
View insider buying and selling activity for Iovance Biotherapeutics or view top insider-selling stocks.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Boxer Capital LLC, Perceptive Advisors LLC, Senator Investment Group LP, Commodore Capital LP, Two Sigma Investments LP, Cubist Systematic Strategies LLC, and BlackRock Inc..
View insider buying and selling activity for Iovance Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $18.64.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $2.92 billion. The biotechnology company earns $-259.58 million in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 241 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected].